GI Medical Oncologist at BC Cancer, Associate Professor at The University of British Columbia, Senior Investigator at the Canadian Cancer Trials Group (CCTG)
Joined March 2014
- Tweets 934
- Following 329
- Followers 847
- Likes 2,356
107 Photos and videos
Jonathan Loree retweeted
May 12
This is an absolutely outstanding review on the management of patients with metastatic gastric cancer.
I may have posted about this review before but it is so good that it deserves another round of applause... Thanks @KlempnerSam @YJanjigianMD @amalsargsyan and all the other co-authors I could not find on X...
Sorry AI, I love you but you are just not there yet. True content experts writing a practical review still beat you easily.
This should be a required read for all who take care of patients with gastric cancer.
nature.com/articles/s41571-0…
3
36
95
6,866
Jonathan Loree retweeted
#CCTG2026 @CDNCancerTrials 🇨🇦
A pleasure to host @JeanneTie to our CCTG Annual Meeting to advance our strong history of trials collaboration with @GICancer #formerlyAGITG 🇦🇺 🇳🇿
Special shout out to her #ILoveCanada earrings! ❤️
1
2
17
603
Jonathan Loree retweeted
Apr 4
🌐 BATTMAN trial begins in MSS metastatic colorectal cancer
On April 1, 2026, Agenus announced that the first patient has been enrolled in the phase III BATTMAN trial.
BATTMAN is a global, randomized phase III study evaluating botensilimab balstilimab vs best supportive care in patients with refractory, unresectable MSS metastatic colorectal cancer.
The trial is being conducted across international sites and represents a potential registrational study in this setting.
@Agenus_Bio @oncodaily @jonathanloree @garo_armen
📎oncodaily.com/oncolibrary/ba…
#OncoDaily #GIOncology #ColorectalCancer #Immunotherapy #ClinicalTrials
1
5
15
543
Jonathan Loree retweeted
Apr 2
Sharing the final publication and schema! @NANETS1 Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors doi.org/10.1530/ERC-25-0303
21
50
3,433
Jonathan Loree retweeted
Mar 4
@OHSUKnight study showed standard dose (35mg/m2 bid) Trifluridine (Lonsurf) wk 1, 3 and 5 of #radiation for stage 2/3 #rectalcancer was safe with TNT. 56% of patients did Watch and Wait.
➡️New option for patients with 5-FU toxicity/contraindications❓
clinical-colorectal-cancer.c…
3
7
616
Jonathan Loree retweeted
Feb 5
Check out our new @NANETS Guidelines for Stage I-III Rectal NETs! Big updates in:
- staging with MRI & PET Dotatate
- advanced excision for < vs. >10 mm tumors
- management of R1 excision
- surgery
- follow-up
@AmanChauhanMD @OncoThor @FlavioRochaMD
doi.org/10.1530/ERC-25-0303
9
15
2,263
Congrats @RobertoFedrigo on your new manuscript on treatment attrition in NETs! Shows how many patients never reach later lines of therapy. Important context as we interpret NETTER-2 and debate earlier PRRT use.
sciencedirect.com/science/ar…
#NETs #PRRT #NETTER2 #oncology
1
1
187
How would you prefer to be screened for colorectal cancer? 🩺
We’re surveying people to better understand preferences — including whether blood-based tests could reduce barriers. Please retweet &
Share your voice: rc.bcchr.ca/redcap/surveys/?…
@BCCancer @bccancerfdn @coloncanada
1
4
7
1,471
Jonathan Loree retweeted
Jan 5
Applications are being accepted for the #CCTG 2026-2027 New Investigator Cancer Trials Practicum - a training program that enables the brightest new Canadian oncology researchers to acquire training & experience in clinical trial conduct. How to apply: buff.ly/pVU9ts3
2
1
262
Jonathan Loree retweeted
AI meets digital pathology! 🔬 We used machine learning on whole-slide images of neuroendocrine tumors to classify grade, differentiation & prognosis.
✍ Authors: Amir Hadjifaradji et al. @jonathanloree @BCCancer @bccancerfdn
🌻 Read in @Cancers_MDPI
mdpi.com/2072-6694/17/18/299…
3
4
202
A nice retrospective study looking at chemo doublets in biliary tract cancer. "FOLFOX Versus FOLFIRI as Second‐Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study - Pircher - 2026" onlinelibrary.wiley.com/doi/…
3
8
678
7 Nov 2025
RT @EricTopol: The "Big Bang" of cancer evolution: for colon cancer, evidence that immune evasion occurs very early
nature.com/articles/s41588-0…
114
1
Jonathan Loree retweeted
4 Nov 2025
So Dill started this to help Canadian patients...
and once he got the platform running for Canada...
he made it global. In a weekend.
Oh, Canada!
@ccranorg @coloncanada
@CAMO_ACOM @CDNCancerTrials @uoftmedicine @Sunnybrook @BCCancer
@GillSharlene @jonathanloree @ocall0
1
1
4
183
23 Oct 2025
Results from DYNAMIC-III RCT of ctDNA-guided adjuvant tx in stage III colon cancer in Nature Med.
🙏 to pts, providers & @JeanneTie
🇨🇦🇦🇺 @CDNCancerTrials & @GICancer Collab
#ESMO2025 Presidential | Supported by @CIHR_IRSC & @cancersociety in 🇨🇦
🔗 rdcu.be/eLTj8
3
3
733
Jonathan Loree retweeted
17 Oct 2025
Excited to be at the #ESMO25 launch of the phase 3 @CDNCancerTrials 🇨🇦 #BATTMAN CO.33
BOT/BAL vs BSC in refractory MSS mCRC #unmetneed #trialsthatmatter
Congrats to @jonathanloree 🙌
@ocall0 @Agenus_Bio
@GICancer @JeanneTie
Let’s get this done! 🇨🇦 🇦🇺 🇫🇷
@coloncanada @ccranorg
@OncoAlert
3
16
57
3,916
Jonathan Loree retweeted
20 Oct 2025
Dr Booth presenting the #CCTG #CO21 #CHALLENGE trial to the GI tumours group at #ESMO2025 - the study was recently published in #NEJM nejm.org/doi/10.1056/NEJMoa2…
2
4
553
Jonathan Loree retweeted
20 Oct 2025
#ESMO25
@CDNCancerTrials
GI disease site is in the house! 🙌
Looking forward to the 🌟 Presidential session later today for DYNAMIC III/CCTG CO.29 🎤 🇨🇦 🇦🇺
📌 ctDNA guided ACT de-escalation in stage3 CC @JeanneTie @jonathanloree
@OncoAlert
@GICancer
#ESMOAmbassadors
8
24
1,230
6 Sep 2025
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
2
7
449
Jonathan Loree retweeted
29 Aug 2025
Exciting science and clinical efficacy in this @MDAndersonNews team science study led by @VanMorrisMD In Cancer Cell.
Triple therapy with IO led to durable responses in BRAF V600E MSS colorectal cancer, showing promise. Randomized study ongoing. #crcsm
cell.com/cancer-cell/fulltex…
6
24
99
6,260
Liquid biopsies in #CRC
🩸 Serial MRD monitoring:
✔️Detects recurrence 8–11 months earlier than imaging
✔️Improves sensitivity from 40–50% to 80–90%
✔️Helps monitor ACT response
Liquid tumor-agnostic assays are evolving: now integrating
✅Methylation
✅Fragmentomics
✅Mutations
annalsofoncology.org/article…
20
61
4,745